浙商证券股份有限公司 关于浙江向日葵大健康科技股份有限公司发行股份及支付现金 购买资产并募集配套资金暨关联交易的核查意见 浙商证券股份有限公司（以下简称"浙商证券"、"保荐人"）作为浙江向 日葵大健康科技股份有限公司（以下简称"向日葵"、"公司"）向特定对象发 行股票项目持续督导阶段的保荐人，根据《证券发行上市保荐业务管理办法》《深 圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等有关规定，对公司拟发行股份及支付现金 购买资产并募集配套资金暨关联交易事项进行了审慎核查，并出具本核查意见： 一、关联交易概述 公司拟通过向上海兮噗科技有限公司（以下简称"上海兮噗"）等交易对方 发行股份及支付现金的方式购买其持有的漳州兮璞材料科技有限公司（以下简称 "兮璞材料"）100%股权，向绍兴向日葵投资有限公司（以下简称"向日葵投资"） 发行股份及支付现金的方式购买其持有的浙江贝得药业有限公司（以下简称"贝 得药业"）40%股权。本次交易完成后，兮璞材料和贝得药业将成为上市公司全 资子公司。具体情况如下： 1、基本情况 2 | 交易形式 | 发行股份及支付现金购买资 ...

（原标题：向日葵龙虎榜数据（9月23日）） 向日葵今日涨停，全天换手率32.42%，成交额27.50亿元，振幅19.00%。龙虎榜数据显示，机构净卖出4654.58万元，营业部席位合计净卖出 2955.92万元。 深交所公开信息显示，当日该股因日收盘价涨幅达20.00%上榜，机构专用席位净卖出4654.58万元。 (产品代码: 560800) ★ 跟踪：中证数字经济主题指数 近五日涨跌：2.47% 市盈率：77.94倍 证券时报•数据宝统计显示，上榜的前五大买卖营业部合计成交3.90亿元，其中，买入成交额为1.57亿元，卖出成交额为2.33亿元，合计净卖出 7610.50万元。 具体来看，今日上榜的营业部中，共有1家机构专用席位现身，即卖二，买入金额69.41万元，卖出金额4723.99万元，合计净卖出4654.58万元。 资金流向方面，今日该股主力资金净流出4.95亿元，其中，特大单净流出4.37亿元，大单资金净流出5801.81万元。近5日主力资金净流出4.31亿 元。（数据宝） 向日葵9月23日交易公开信息 | 买/卖 | 会员营业部名称 | 买入金额（万元） | 卖出金额（万元） | | --- | ...

Market Overview - The Shanghai Composite Index fell by 0.18% on September 23, with five industries experiencing gains, led by the banking and coal sectors, which rose by 1.52% and 1.11% respectively [1] - The social services and retail trade sectors saw the largest declines, down by 3.11% and 2.90% respectively [1] - The pharmaceutical and biotechnology industry also declined by 1.93% [1] Capital Flow Analysis - The main capital outflow from the two markets totaled 996.85 billion yuan, with only three industries seeing net inflows: banking (14.00 billion yuan), construction and decoration (1.69 billion yuan), and coal (399.41 million yuan) [1] - The electronics industry experienced the largest net outflow, totaling 200.43 billion yuan, followed by the computer industry with a net outflow of 166.60 billion yuan [1] Pharmaceutical and Biotechnology Sector - The pharmaceutical and biotechnology sector saw a net outflow of 81.15 billion yuan, with 474 stocks in the sector; 32 stocks rose while 441 fell [2] - The top net inflow stocks in this sector included Amgen Pharmaceuticals-U with a net inflow of 114.11 million yuan, followed by China National Pharmaceutical and Guangsheng Tang with inflows of 74.18 million yuan and 73.03 million yuan respectively [2] - The sector's outflow leaderboard featured WuXi AppTec with a net outflow of 65.79 million yuan, followed by Bory Pharmaceutical and Sunflower with outflows of 56.65 million yuan and 49.46 million yuan respectively [4]

向日葵今日涨停，龙虎榜数据显示，上榜营业部席位全天成交3.9亿元，占当日总成交金额比例为 14.18%。其中，买入金额为1.57亿元，卖出金额为2.33亿元，合计净卖出7610.5万元。具体来看，机构 买入69.41万元，卖出4723.99万元，合计净卖出4654.58万元。此外，东兴证券北京复兴路证券营业部、 国泰海通证券上海长宁区江苏路证券营业部分别买入3580.86万元、3084.93万元；浙商证券台州环城东 路证券营业部、国金证券成都高新区交子大道证券营业部分别卖出9701.06万元、2837.28万元。截至9月 23日收盘，向日葵涨20%，全天换手率达32.42%，振幅达19.16%，全天成交27.0亿元，近5个交易日累 计涨43.95%，近30个交易日累计涨80.3%。 ...

Group 1 - The core point of the article highlights that the trading volume of Sunflower has reached 1.142 billion yuan, marking the highest level since September 10, 2020 [2] - The latest stock price of Sunflower has increased by 6.05%, with a turnover rate of 13.61% [2] - The previous trading day's total transaction volume for the stock was 131 million yuan [2] Group 2 - Zhejiang Sunflower Health Technology Co., Ltd. was established on March 21, 2005, with a registered capital of 1.287 billion yuan [2]

Group 1 - The chemical pharmaceutical sector increased by 0.22% on September 22, with Sunflower leading the gains [1] - The Shanghai Composite Index closed at 3828.58, up 0.22%, while the Shenzhen Component Index closed at 13157.97, up 0.67% [1] - Notable gainers in the chemical pharmaceutical sector included Sunflower, which rose by 19.96% to a closing price of 5.95, and Frontier Biotech, which increased by 5.84% to 15.76 [1] Group 2 - The sector experienced a net outflow of 1.368 billion yuan from institutional investors, while retail investors saw a net inflow of 908 million yuan [2] - Major stocks with significant net inflows from retail investors included Sunflower, which had a net inflow of 55.9352 million yuan [3] - Conversely, stocks like Hengrui Medicine experienced a net outflow of 62.0948 million yuan from retail investors [3]

Core Viewpoint - The company plans to acquire 100% equity of Xipu Materials and 40% equity of Beid Pharmaceutical through a combination of share issuance and cash payment, aiming to enhance asset quality and long-term development [1] Group 1: Acquisition Details - The company will purchase 100% equity of Xipu Materials from six counterparties, which specializes in high-end semiconductor materials, including high-purity electronic special gases and silicon-based precursors [1] - The company will also acquire 40% equity of Beid Pharmaceutical, a subsidiary engaged in the research, manufacturing, and sales of various drugs [1] Group 2: Strategic Implications - This transaction is expected to improve the company's asset quality and promote long-term growth [1] - Post-transaction, the company will enter the high-end semiconductor materials sector, creating a second growth curve and accelerating the transition to new productive forces [1] - The move aims to generate new profit growth points, thereby enhancing the company's sustainable profitability [1]

Group 1 - Global Printing announced that shareholder Hong Kong Yuanshi International Co., Ltd. plans to reduce its stake by up to 3.2004 million shares, accounting for 1% of the total share capital, due to personal funding needs [1] - Sunflower intends to acquire 100% equity of Xi Pu Materials and 40% equity of Zhejiang Beid Pharmaceutical through a combination of share issuance and cash payment, with stock resuming trading on September 22, 2025 [1][2] - Crown Zhong Ecology is planning a change in control, leading to a temporary suspension of its stock and convertible bonds due to significant uncertainties [2] Group 2 - China Oil Engineering's wholly-owned subsidiary signed a $513 million EPC contract for an LNG pipeline project in the UAE, covering approximately 180.5 kilometers of natural gas pipeline with a 36-month construction period [3] - Shanxi Fenjiu announced that shareholder Huachuang Xinrui (Hong Kong) Co., Ltd. plans to reduce its stake by up to 16.2006 million shares, representing no more than 1.33% of the total share capital [4] - Brother Technology's subsidiary received a drug registration certificate for Iopamidol injection, which is included in the national medical insurance catalog [5] Group 3 - Lin Yang Energy is expected to win a bid for a metering equipment project from the State Grid, with an estimated total bid amount of approximately 142 million yuan [6] - Huahai Chengke received approval from the China Securities Regulatory Commission for issuing shares and convertible bonds to purchase assets and raise no more than 800 million yuan in matching funds [8] - Jindi Co. signed a framework agreement to acquire controlling interest in Unico Precision, which specializes in manufacturing gears and automotive parts [10] Group 4 - Ruifeng High Materials announced that its major shareholder plans to reduce its stake by up to 2.4 million shares, accounting for 0.9584% of the total share capital [12] - Changliang Technology's director plans to reduce his stake by 1.05 million shares, representing 0.129% of the total share capital [14] - Zhongjing Food's director plans to reduce his stake by up to 150,000 shares, accounting for 0.10% of the total share capital [16] Group 5 - Haitai Technology announced that two shareholders plan to reduce their stakes by a total of up to 2.53% of the total share capital [18] - Zhenlei Technology's chairman is under detention but the company states that control has not changed and operations remain normal [20] - Huakang Co. plans to distribute a cash dividend of 0.2 yuan per share, totaling approximately 60.61 million yuan [19]

中国经济网北京9月22日讯 向日葵(300111.SZ)今日开盘涨停，截至发稿报5.95元，涨幅19.96%。9 月5日，公司股价收报4.96元，涨幅11.96%。 公司昨晚披露关于披露本次交易相关预案暨公司股票复牌及一般风险提示性的公告，公司拟以发行 股份及支付现金的方式购买漳州兮璞材料科技有限公司100%股权、浙江贝得药业有限公司40%股权并 募集配套资金。根据深交所相关规定，经公司申请，公司A股股票自2025年9月8日（星期一）上午开市 起停牌；经申请，公司股票将于2025年9月22日（星期一）上午开市起复牌。 | | | 单位:万元 | | --- | --- | --- | | 资产负债表项目 | 2024年12月31日 | 2023年12月31日 | | 资产总额 | 47.792.97 | 48,500.49 | | 负债总额 | 13.605.34 | 15.699.74 | | 所有者权益合计 | 34.187.63 | 32,800.75 | | 利润表项目 | 2024 年度 | 2023 年度 | | 营业收入 | 33.036.87 | 33.594.76 | | 营业利润 | 1, ...

Group 1 - The company, Sunflower, has announced a non-public issuance plan to acquire 100% equity of Xipu Materials and 40% equity of Beid Pharmaceutical, which is expected to constitute a major asset restructuring for the listed company [2] - Prior to this transaction, the company's main business focused on the pharmaceutical sector, including the research, manufacturing, and sales of anti-infection, cardiovascular, and digestive system drugs [2] - Xipu Materials specializes in the research, manufacturing, and sales of high-end semiconductor materials, with products used in critical processes of semiconductor manufacturing [2] Group 2 - The acquisition is expected to enhance the asset quality of the listed company and promote its long-term development [2] - Post-transaction, the company will enter the high-end semiconductor materials sector, creating a second growth curve and accelerating its transformation towards new productive forces [2] - This move aims to add new profit growth points for the company [2]